Skip to main
BMEA
BMEA logo

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. has demonstrated significant progress in its clinical programs, particularly with icovamenib, which reported a 1.2% reduction in HbA1c after 52 weeks in severe insulin-deficient Type 2 diabetes patients, indicating strong therapeutic efficacy. Additionally, the company has initiated Phase I trials for BMF-650, showing promising preclinical results in weight reduction and glycemic control, which enhances the potential for advancing its metabolic disease pipeline. Financially, Biomea Fusion has reduced its net loss from $32.8 million in Q3 2024 to $16.4 million in Q3 2025, reflecting improved capital efficiency as it simultaneously seeks to bolster its pipeline through an equity and warrant offering.

Bears say

Biomea Fusion Inc. reported a significant decrease in R&D expenses for Q3 2025, amounting to $14.4 million, compared to $27.2 million in Q3 2024, indicating a potential reduction in investment in critical drug development. Additionally, general and administrative (G&A) expenses also declined from $6.8 million to $4.2 million, reflecting a tightening of operational costs. The downward adjustment of the price target from $16.00 to $12.00 based on the new share count raises concerns about the company's growth prospects and overall financial health.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.